CHESTERTONS-GLOBAL
6.5.2021 08:02:11 CEST | Business Wire | Press release
Global estate agency, Chestertons Global Franchise Holdings Limited, today announced that Chestertons Cyprus has joined its expanding network, which has seen rapid growth over the past year.
Since Chestertons Ionian, headquartered in Corfu, was welcomed on board as the first Global Franchise Partner in early March 2020, the business has gone from strength to strength, with new teams joining the Chestertons network in the following locations: Barbados, Antigua & Barbuda, Portugal, Morocco, the Costa del Sol, Gibraltar and now Cyprus.
Chestertons Cyprus, headed up by Principal Andrew Constantinou, has launched its first office in Paphos, with plans for additional offices in the works. With the Portugal and Costa del Sol openings bringing five offices apiece to the network, the new franchise offering has secured 16 offices in total to date, increasing the number of property listings on the global business’ books by 300%.
The expansion of the franchise business means Chestertons’ geographic reach (in terms of physical office presence) has expanded from 15 countries in Q1 2020 to 21 today, an increase of 40%.
Jamie McMullan, Chief Operating Officer, Chestertons Franchising UK & Europe, comments: “The marketing, technological and brand heritage clout which we offer our partners has proved highly attractive, equipping them with the network and tools to enhance their services. The franchising model also offers local experts the chance to grow their businesses, with the backing of a global network of expertise and support.
“Building on the impressive growth seen over the last year, our franchise offering is attracting interest from across Asia, the Americas and additional European locations. We continue to be on the lookout for like-minded partners that can share in our brand, technology and extensive international network .”
The Global New Homes team has also reported significant growth over the last year, as it strives to work with the most prestigious developers on globally renowned projects. In 2020 the team, headquartered in Dubai, introduced seven additional new homes desks including in Hong Kong and Qatar, further expanding their network of lifestyle purchasers and investors.
The number of locations marketed by the Global New Homes team on a country basis has increased by 30% in the last 12 months to now include Japan, Thailand, Greece and Cyprus. The volume of new developments on the team’s books is up 40% since the first quarter of 2020, and includes the exclusive marketing in the Middle East and North Africa region of Fairmont Royal Palm Marrakech , and working with the likes of Barratt London and EcoWorld to launch homes to markets in the Middle East.
All-in-all buyer enquires for new homes are up 15% annually (Q1 2020 vs Q1 2021).
Dennis Chan, Global Head of International Sales, comments: “Appetite for real estate remained robust over the past 12 months, albeit in a challenging global environment amid the pandemic. With vaccination programmes underway, there is now a sense the pandemic is easing and, with the possibility of international travel resuming over coming months, buyers can take advantage of citizenship programmes, remote working visas, or financial incentives offered by developers in sought after destinations across the world.
“In this context, our clients and buyers have seen renewed value in our offering, which deploys our global team’s diverse skillsets to make their lives as straightforward as possible in what can be a complex process.”
To learn more about global franchising opportunities go to: www.chestertons.com/franchising
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005826/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom